Fabino Enterprises Limited (BOM:543444)
India · Delayed Price · Currency is INR 13.91
-0.70 (-4.79%)
At close: Jan 16, 2026
Fabino Enterprises Revenue
Fabino Enterprises had revenue of 66.33M INR in the half year ending September 30, 2025, a decrease of -48.42%. This brings the company's revenue in the last twelve months to 204.36M, up 63.85% year-over-year. In the fiscal year ending March 31, 2025, Fabino Enterprises had annual revenue of 180.54M, down -14.37%.
Revenue (ttm)
204.36M
Revenue Growth
+63.85%
P/S Ratio
0.14
Revenue / Employee
22.71M
Employees
9
Market Cap
29.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 180.54M | -30.29M | -14.37% |
| Mar 31, 2024 | 210.83M | 177.22M | 527.34% |
| Mar 31, 2023 | 33.61M | -8.40M | -20.00% |
| Mar 31, 2022 | 42.01M | 11.43M | 37.39% |
| Mar 31, 2021 | 30.57M | -44.59M | -59.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 663.49M |
| Beryl Drugs | 191.97M |
| Decipher Labs | 176.11M |
| Brawn Biotech | 168.03M |
| Unjha Formulations | 141.50M |
| Colinz Laboratories | 58.72M |
| Ganga Pharmaceuticals | 26.93M |
| Cresanto Global | 5.80M |